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 Creatine is necessary to transfer energy between cellular 
compartments. Creatine is converted to phosphocreatine by the creatine 
kinase reaction within mitochondria and phosphocreatine generates 
adenosine triphosphate (ATP) in the cytoplasm. ATP powers most of the 
energy consuming reactions in cells. Defects in creatine synthesis or 
transport disrupt this process and result in brain creatine deficiency 
syndromes. Affected patients have developmental delay, hypotonia, 
autism, seizures, and impaired motor skill development. Defects of 
creatine synthesis are caused by impaired activity of the enzymes 
guanidinoacetate methyltransferase (GAMT) and arginine:glycine 
amidinotransferase (AGAT), both transmitted as autosomal recessive 
traits, whereas defect in creatine transport (SLC6A8 Gene) are transmitted 
in an X-linked recessive manner. Patients with defects in creatine 
synthesis respond to creatine supplementation and dietary manipulations. 
This therapy is more effective if initiated before mental retardation is 
evident. For this reason, diagnosis should be accomplished as soon as 
possible with newborn screening. Here we report a reliable three-tier 
testing method for screening for GAMT and AGAT deficiency in newborns’ 
 v 
 
blood spots. Creatine and guanidinoacetate are detected in newborn 
screening blood spots by tandem mass spectrometry (MS/MS). Second-
tier testing using LC-MS/MS confirms more quantitatively low creatine and 
increased or decreased guanidinoacetate levels, while third-tier testing 
consists of DNA sequencing to identify mutations in the GAMT and AGAT 
Genes. This test can potentially identify newborns with GAMT and AGAT 
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 Newborn screening began in the 1960s when a test for a metabolic  
 
disorder, phenylketonuria (PKU), was developed by Robert Guthrie (Newborn  
 
Screening 2011). Guthrie knew that treatment for PKU is more effective if  
 
initiated at the earliest date possible and could prevent mental retardation. This  
 
general concept applies to many other disorders, including the defects of creatine  
 
synthesis GAMT and AGAT deficiencies (O’Rourke, et al., 2008, Battini, et al.,  
 
2006). Newborn screening could potentially detect these conditions and prevent  
 
irreversible damages that occur without treatment.  
 
 Creatine, or α-N-methylguanidino acetic acid, is an amino acid necessary  
 
for energy metabolism.  Creatine was initially recognized as deriving from meat  
 
(kreas in Greek meaning flesh) in 1832 (Longo et al., 2011). Creatine is  
 
phosphorylated to phosphocreatine that can release phosphate to yield energy 
 
 and convert ADP to ATP (Verhoeven et al., 2005). In tissues requiring high  
 
levels of energy, such as muscle, brain, and heart, creatine is especially  
 
important for normal functioning. Creatine is synthesized by the body in the liver,  
 
pancreas, and kidneys (Battini, et al., 2006) and is then distributed to all tissues  
 






phosphorylated form, phosphocreatine, spontaneously break down to creatinine  
 
that is excreted in the urine (Skyut-Cegielska et al., 2004). The creatinine lost in  
 
urine excretion is directly proportional to creatine intake (Battini, et al., 2006).  
 
Creatinine loss must be restored by new synthesis and dietary intake.  In  
 
humans, approximately half of the daily creatine required is taken in through diet  
 
from meat, fish and dairy products. The remaining creatine needed must be  
 




GAMT and AGAT Deficiency 
 
 Two enzymes are necessary for the synthesis of creatine:  
 
guanidinoacetate methyltransferase (GAMT, OMIM 601240) and arginine:  
 
glycine amidinotransferase (AGAT or GATM, OMIM 602360) (Almedia, et al.  
 
2004; Longo et al., 2011). Creatine is metabolized in a two-step process (Fig. 1).  
 
The first step is the transfer of an amido group from arginine to glycine. This  
 
step produces guanidinoacetic acid and ornithine (Skyut-Cegieslska, et al.,  
 
2004). The second step in creatine synthesis involves the transfer of a methyl  
 
group from S-adenosylmethionine to guanidinoacetate (GAA) to produce  
 
creatine and S-adenoslyhomocysteine (Dhar et al., 2008). Once creatine is  
 
synthesized, it is transported to the brain and muscle via the blood circulation.  
 
Creatine can enter cells and tissues through specific membrane transporters,  
 
the most important of which is the sodium and chloride dependent creatine  
 
transporter 1 (CT1, CRTR, CRT, OMIM 300036) encoded by the SLC6A8 Gene  
 






Figure 1. Creatine synthesis and transport. Creatine is synthesized from the 
amino acids arginine and glycine through the action of the enzymes AGAT and 
GAMT. AGAT synthesizes guanidinoacetate to which a methyl group is added 
from S-adenosylmethionine by GAMT to generate creatine. Creatine enters cells 
and the brain through the CT1 creatine transporter encoded by the SLC6A8 
Gene. Metabolism of creatine leads to formation of creatinine that is excreted in 




 Brain creatine deficiency syndromes are a group of rare disorders that  
 
include two recessive conditions that impair the synthesis of creatine (GAMT  
 
deficiency, OMIM 612736; and AGAT deficiency, OMIM 612718) or its transfer to  
 
the brain (X-linked recessive SLC6A8 creatine transporter deficiency, OMIM  
 
300036)) (Longo et al., 2011) (Fig. 1). These disorders are characterized by brain  
 
creatine deficiency, detectable by magnetic resonance spectroscopy (MRS)  
 
(Longo et al., 2011; Skyut-Cegieslska, et al., 2004). Affected patients have  
 
mental retardation, hypotonia, autism, behavioral problems and seizures (Dhar et  
 




























 Their real incidence is unknown, but some studies indicate that up to 2.7%  
 
of X-linked mental retardation cases could be due to creatine deficiency  
 
syndromes. These conditions were only recently discovered: GAMT deficiency  
 
was initially reported in 1994 (Nasrallah, et al., 2010) and AGAT deficiency in  
 
2001 (Verhoeven et al., 2005). Many physicians are unfamiliar with these  
 
disorders and confuse their symptoms with other more common conditions. It is  
 
also difficult to obtain testing for these disorders because few laboratories offer  
 
diagnostic testing (Nasrallah, et al., 2010). 
  
 Therapy for the two defects in the biosynthesis of creatine, GAMT and  
 
AGAT deficiencies, consists in the administration of creatine supplements. In  
 
GAMT deficiency, the synthesis of guanidinoacetate is also prevented by  
 
administration of ornithine (the product of the reaction), restriction of arginine  
 
(one substrate of the reaction), and administration of benzoate that binds to  
 
glycine reducing its levels (glycine is the other substrate of the reaction). With  
 
treatment, seizures improve and development progresses. Treatment before  
 
symptoms appear has been shown to prevent mental retardation. If an accurate  
 
and reliable screening test for these conditions was available, the criteria for  
 
inclusion in newborn screening programs would be met. The purpose of the  
 
study was to evaluate the feasibility of including additional markers of creatine  
 
deficiency syndromes, specifically creatine and guanidinoacetate in the newborn  
 


















 Newborn screening is a public health activity that started in the early 
1960s thanks to Dr. Robert Guthrie, who developed a screening assay for 
phenylketonuria (PKU) from newborns’ blood spotted and dried on filter paper 
(Newborn Screening 2011). Since then millions of infants in the United States 
and in the world have been screened for a variety of genetic disorders. In the last 
ten years tandem mass spectrometry (MS/MS) has been introduced in newborn 
screening laboratories, allowing multiplex analysis of several analytes from only 
one sample.  The use of MS/MS has allowed the expansion of newborn 
screening, which now includes 30+ disorders.  
 The aim of newborn screening is the early identification and treatment of 
conditions that would not be detected before severe complications, such as 
irreversible organ damage or death, occur. New conditions are included in a 
newborn screening program only if certain criteria are met. These criteria 
evaluate the characteristics of the disease, the test used to screen for it, and the 
newborn screening program. The disease to be screened must be serious and 





treatment must be available. The screening test must be reliable, valid, and 
affordable.  
 Most metabolic disorders fit all of these criteria and can be detected in the 
newborn period by tandem mass spectrometry. Two main classes of metabolites 
are detected by this technique: amino acids and acylcarnitines. Amino acids 
become elevated in certain aminoacidopathies (e.g., PKU, tyrosinemia, and 
maple syrup urine disease), while the study of the acylcarnitine profile can 
identify defects of fatty acid oxidation (e.g., medium-chain acyl-CoA 
dehydrogenase deficiency (MCAD) and very long-chain acyl-CoA 
dehydrogenase deficiency(VLCAD)) and organic acidemias (e.g., propionic 
acidemia, methylmalonic acidemia, and glutaric acidemia type 1).  
 
 
Tandem Mass Spectrometry Methodology 
 
 Tandem mass spectrometry measures the ratio of the mass (m) of a 
chemical to its charge (z). A small punch (4.7 mm diameter) of whole blood 
collected on filter paper provides the sample needed for MS/MS analysis. The 
sample is extracted with methanol containing deuterated internal standards. After 
drying the extract, amino acids and acylcarnitines are derivatized to butylesters. 
The derivatized mixture is dried, reconstituted with a solvent that is compatible 
with the mobile phase, then injected in the mass spectrometer.  
 All molecules are first ionized, typically by electrospray. The ions formed 
are then separated according to their mass to charge (m/z) ratios. Since most of 





the masses of the molecules ionized in this process. Two mass spectrometers 
are used in tandem to separate and analyze mixtures of compounds, such as 
amino acids and acylcarnitines.  After the ions are separated by the first mass 
spectrometer, they enter the “collision cell” where they are broken down into 
fragments by collision with a neutral gas. The fragments pass through a second 
mass spectrometer that separates them according to their mass to charge (m/z) 
ratio (Kushnir 2010).  
 The acquisition of data by MS/MS can be accomplished in two different 
ways. First by class specific analysis where each molecule has a characteristic 
fragmentation pattern and classes of compounds will fragment in a similar way. 
For example, all acylcarnitines will produce a similar fragmentation pattern. With 
the second type of acquisition, target compound analysis, one can derive 
information about a specific class of compounds. The focus is on one component 
of the sample.  Labeled internal standards (amino acids and acylcarnitines with 
the same chemical and physical properties of the natural analogues but with 
higher mass/charge ratio due to the presence of stable isotopes such as 
deuterium or carbon-13) are added to the extraction mixtures to quantify the 
different species. The analysis is very fast (<2 minutes) and suitable for high 
throughput application. With the MS/MS platform, it is also easy to increase the 












 De-identified blood spots, remaining from newborn screening, were used 
in this study. This study was approved by the IRB of the University of Utah and of 
the Utah Department of Health. After extraction and derivatization, the samples 
were injected onto a Waters BEH C18 1.7µm 2.1x100 mm and analyzed in a 
Waters Xevo TQ MS. The deuterated internal standard d-2-guanidinoacetate was 
purchased from DCN Isotopes. Hydrochloric acid (3N) in butanol, used for the 
derivatization step, was purchased from Regis Technologies.  Methanol (MeOH) 




Dried Blood Spot Preparation 
 
 Packed red blood cells were obtained from Blood Services at ARUP. The 
blood cells were washed 3 times with a 0.9% saline solution. After the final 
washing, the hematocrit was measured and it was adjusted to a final value of 
55% by diluting the blood cells with serum. This was used to prepare standards 






 Diluted packed red blood cells were used to prepare standards with the 
same matrix as the samples. For this study we focused on the identification of 





following concentrations: 0, 1µM, 4µM, 20µM, and 40µM. Once the calibrators in 
blood were prepared, they were spotted on filter paper and allowed to dry. 
Following the extraction protocol described below, a time course was performed 
to evaluate the best extraction time for guanidinoacetate. 
 
 
Extraction and Analysis 
 
 The extraction procedure for the first tier test is the same procedure used  
 
(at ARUP) for newborn screening to detect amino acids and acylcarnitines  
 
(routine screening), with the addition of internal standards for guanidinoacetate  
 
and creatine. With the second tier test, samples determined to have an elevated  
 
guanidinoacetate by first tier testing, are analyzed using LC-MS/MS. With this  
 
system, the chromatographic separation allows detection of possible isobaric  
 
interferences (fragments that have the same mass to charge ratio of  
 






































 This procedure follows the main extraction protocol used for the newborns’ 
spots. Punches (4.7 mm) of dried blood spots (standards, controls, and “normal” 
newborns’ blood spots) were placed in 96-well flat bottom plates; 200 µL of 
methanol containing internal standards (amino acids, acylcarnitines, 
succinylacetone, and guanidinoacetate) were added to each well. After a 5 
minute incubation at ambient temperature, 100 µL of 3mM hydrazine hydrate in 
water were added to each well.  The plate was placed in an incubator at 37°C 
and rotated at 110 revolutions per minute (rpm) for 25 minutes (after evaluating 
time course results). The supernatant was transferred to 96-well round bottom 
plates and dried under nitrogen.  Butanolic hydrochloric acid (50 µL) was added 
to the wells to convert analytes into butyl-derivatives. After 15 minutes incubation 
at 65⁰C, the samples were dried under nitrogen, reconstituted with 200 µL of a 
50/50 mixture of acetonitrile and water containing 0.02% formic acid, and injected 










 Punches (4.7 mm) of dried blood spots (standards, controls, and  
newborns’ blood spots) were placed in 96-well flat bottom plates; 200 µL of 
methanol containing internal standards were added to each well. Then the 96 
well plates were covered and put on a shaker, at a medium-high setting, for 15 
minutes. The solvent was then transferred from all 96 wells into another 1mL 96 
well plate. The plate was dried for 10 minutes under a SPE-Dry 96 Nitrogen 
evaporator and then allowed to cool for 2 minutes. The samples were derivatized 
with 100µL of 3N hydrochloric acid in butanol. The plate was shaken at a high 
setting for 2 minutes. Then it was put into an incubator at 65⁰C with a heated 
metal block on top for 20 minutes.  The plate was dried under nitrogen again 
using the previous conditions. Then the samples were reconstituted with 50µL of 
70:30 water/acetonitrile and shaken. Aliquots of the samples were injected (5µL) 




































 Guanidinoacetate standards prepared in methanol, water, and in blood at 
several concentrations were spotted on filter paper, dried, and extracted 
according to the above protocol, using three different extraction times: 15 
minutes, 30 minutes, and 45 minutes. The results were compared (Figures 2 and 
3). The recovery of guanidinoacetate was independent of the extraction time. The 




Figure 2. Guanidinoacetate  standards prepared in water and spotted on filter 






                                                         




This is the time routinely used for the extraction of acylcarnitines and amino 
acids. The solvent used for the extraction of guanidinoacetate is the same 
solvent routinely used for the newborn screening application. 
 
 
Stability of Guanidinoacetate in Dried Blood Spots 
 
 For our study we used leftover blood spots, which had been stored for at 
least three months. We first assessed the stability of guanidinoacetate in dried 
blood spots stored at different temperatures (ambient, 2-8°C, and – 20°C and 
lower). We used standards prepared in blood at several concentrations and 
spotted on filter paper. The dried blood spots, after drying for 24 hours at ambient 
temperature, were stored in a sealed bag with a desiccant, in the three 
temperature environments. The dried blood spots were tested in triplicate the day 
they were prepared, then daily for 3 days, weekly for 2 weeks, and monthly for 2 





                     
Figure 4. Dried blood spots spiked with guanidinoacetate and kept at room 












Figure 6. Guanidinoacetate recovery from dried blood spots kept at -20⁰C.    
 
 
                                                    
The results obtained at different concentrations and temperatures do not show 
significant changes with time. Therefore guanidinoacetate is stable in the dried 
blood spots, for at least 2 months. 
 
 
Analysis of Guanidinoacetate in Newborns’ Blood Spots 
 
 To confirm that patients with GAMT deficiency and elevated 
guanidinoacetate could be identified by newborn screening using this method, we 
analyzed 163 previously-tested negative newborns’ blood spots, deidentified by 
the Utah Department of Health according to their internal protocol, and one blood 
spot from a patient with GAMT deficiency (blood spots were obtained after 
parental informed consent, according to a protocol approved by the IRB of the 











Healthy Population  n=163                           Deficient Population  n=1  
 
Normal         Guanidinoacetate   Creatine 
Newborns’              (µM)                  (µM)            
 
Average ±SD  1.42 (± 0.54)     506.95 (±142.4) 
 
%CV                38.35                28.10 
 
Median            1.33                  465.63 
 
GAMT           Guanidinoacetate Creatine 
Patient #1                (µM)                (µM)           
 
1st Screen   33.16                  451.34 
 
2nd Screen        10.45                  167.06 
 
 
SD is the standard deviation and %CV is the coefficient of variation.  
 
 
 The guanidinoacetate concentration determined in negative blood spots is 
significantly different (lower) than the concentration of the patient with GAMT 
deficiency, indicating that this method can be used to identify patients with GAMT 



































 Platinum Taq DNA Polymerase and 10 mM dNTP Mix were purchased 
from Invitrogen. ExoSAP-IT was purchased from Affymetrix. Lamda DNA/HindIII 
Marker 2 ladder was purchased from Fermentas. Dimethyl sulfoxide, ethylene 
glycol, and betaine (PCR grade) were purchased from Sigma Aldrich. The 
Failsafe™ PCR PreMix Selection Kit buffers were purchased from Epicentre 
Biotechnologies.  All other reagents were prepared or used from an in house 





 The GAMT Gene is composed of 6 exons on chromosome 19 (Nasrallah, 
et al., 2010) (Fig. 7) from base pair 1,348,087 to base pair 1,352,551. 
Chromosome 19 is gene rich with almost 1500 genes and has more than twice 
the gene density of the genome-wide average. Chromosome 19 was completely 
sequenced in 2004 and contains genes that code for diseases such as insulin-
dependent diabetes, breast cancer, migraine headaches, and Alzheimer’s 





Figure 7. Guanidinoacetate methyltransferase:  Schematic of the gene and the 




GAMT provides the information for production of the enzyme guanidinoacetate 
methyltransferase. This enzyme is active in the liver, pancreas,and in the 
kidneys.  The GAMT enzyme is a necessary component for the second step of 
the creatine biosynthetic pathway in which creatine is produced from 
guanidinoacetate (Verhoeven, et al., 2005).  
 Primers for the GAMT Gene’s 6 exons were designed using the UCSC 
Genome browser and then checked with other online programs to avoid sites of 
single nucleotide polymorphisms and regions of homology with other genes. 
Exons 2 and 3 are very close and could be amplified in the same reaction. To 





products using the same M13 sequence as it is standard at ARUP Laboratories.  





 The polymerase chain reaction (PCR) is an enzymatic process in which a 
specified region of deoxyribonucleic acid (DNA) is replicated numerous times to 
enable further studies (Sambrook, 2001). In the polymerase chain reaction, DNA 
is heated to separate the two strands of DNA, specific primers complementary to 
the DNA sequence are annealed at a lower temperature, and DNA is copied 
using the Taq polymerase capable of working at high temperatures (72⁰C) and 
being resistant to the elevated temperatures needed to denature the DNA 
between cycles (>90⁰C).  This process is repeated for 30-40 cycles to generate 
copies of the desired sequence. The primers are the most important aspect for 
developing a PCR protocol. The two primers, forward and reverse, are short DNA 
sequences that flank the area that will be copied.  
 The polymerase chain reaction can be used to sequence the DNA of 
patients with genetic conditions. PCR can confirm or exclude their diagnosis 
(Item et al., 2004). For this project, PCR was used to amplify and sequence 
genes that can cause brain creatine deficiency. 
 For the GAMT Gene, DNA was used at 50 nanograms per microliter (final 
content was 2.5 nanograms per tube) in a standard reaction containing 10 mM 
dNTPs (final concentration 0.2mM each), 10x buffer (final concentration 1x), 50 













with M13 Tail / 
base pairs 
Forward Primer with 
M13 Tail (5’-3’) 
Reverse Primer with 





























cgagaccctggactc 55 59 
Primers were designed on July 2, 2010. M13 tails are in black. The GC column 
shows percent guanine-cytosine in the primers. The last column, Est. Tm, is for 
the estimated melting temperature. 
 
  
1 unit per tube), nanopure™ water, and the forward and reverse primers at 
concentrations of 10 mM (final concentration of 0.2µM each). The protocol used 
was a denaturation step of 30 seconds at 94⁰C, an annealing step for 30 
seconds at 55⁰C, and an extension time of 1 minute at 72⁰C with a total of 30 
cycles run using an Eppendorf Mastercycler Gradient (a PCR machine). Once 
the cycles were complete the PCR products were mixed with blue loading dye 
and put into a 1% agarose gel with ethidium bromide added. The gel was 
electrophoresed at 72 volts for 1 hour and the results were photographed with 
ultraviolet light.  
 The initial experiments generated nonspecific bands and occasional failed 
amplification. This required redesign of primer 6, the use of a different thermal 





touchdown, fail-safe buffers, and enhancing agents. These techniques and 
enhancers were used because the GAMT Gene and related primers are very 
guanine-cytosine rich, rendering the denaturation process more difficult (GC 
bonds require higher temperature for denaturation).   
 Hot start consisted of adding the polymerase after the DNA had been fully 
denatured. In a conventional polymerase chain reaction, the Taq DNA 
polymerase is active at room temperature and to a lesser degree, even on ice. In 
some instances, when all the reaction components are put together, nonspecific 
primer annealing can occur due to these low temperatures. This nonspecific 
annealed primer can then be extended by the Taq DNA polymerase, generating 
nonspecific products and lowering product yields. Adding the polymerase at time 
of the first annealing can increase yield and specificity of PCR (Sambrook, 2001). 
 Touchdown PCR is used to optimize PCR, increasing specificity, 
sensitivity and yield (Sambrook, 2001). With this method, the initial annealing 
temperature is higher than the projected melting temperature (Tm) of the primers 
being used, then progressively transitions to a lower, more permissive annealing 
temperature over the course of successive cycles. As the temperature 
approaches the one of the specific primer, this will be able to anneal to the 
correct sequence and initiate amplification, but not the amplification of other 
sequences, thus increasing the specificity. In the case of the GAMT Gene, all 
primer sets could be performed at the same time.  
 Failsafe™ buffers (Epicentre Biotechnologies) are pre-mixed buffers 





function better at defined conditions including high guanine-cytosine content. 
With our GAMT primers, buffer G gave the best results.  
 A variety of PCR additives and enhancing agents have been used to 
increase the yield, specificity and consistency of PCR reactions. Whilst these 
additives may have beneficial effects on some amplifications it is impossible to 
predict which agents will be useful in a particular context and therefore they must 
be empirically tested for each combination of template and primers. Enhancing 
agents can stabilize the structure of DNA or the polymerase and increase 
amplification. Dimethyl sulfoxide (DMSO), betaine, ethylene glycol, and 
propanediol were investigated as enhancing agents. These agents have been 
used to increase product yield of primers that are guanine-cytosine rich (Zhang, 
et al., 2009). Problems arise with guanine-cytosine rich primers such as 
decreased separation of the strands from the numerous guanine-cytosine bonds, 





 Table 3 summarizes the PCR conditions and protocol that were developed 
to amplify all GAMT exons. The protocol was designed to allow all GAMT primers 
to work using the same conditions. Given the small size of the bands generated, 
a 2% agarose gel rather than the standard 1% was used to allow better 
movement of the small amplicons. 
 Figure 8 shows successful amplification of all amplicons (exons 2 and 3 














2X PreMix G 
12.25 µL 1X  touchdown 
Primer F 10mM 0.5 µL 0.2 µL Hot Start 5 minutes at 95⁰ 
Primer R 10mM 0.5 µL 0.2 µL Denaturation 30 seconds at 94⁰ 
template DNA 50 
ng/µL 
1 µL 2 ng Annealing 45 seconds at 62⁰ 
Platinum Taq  
5 U/µl 
0.5 µL 1 unit 62-57⁰ Decrease in temp. 
each cycle until 57⁰ 
water 10.25 µL  Elongation 1 min at 72⁰ 




length in base pairs is also shown. Samples were subsequently cleaned with 
Exosap, a single-step enzymatic cleanup of PCR products that eliminates 
unincorporated primers and dNTPs, and submitted to ARUP Laboratories 
sequencing facility for analysis. Figure 9 shows an example of the sequence 
obtained (Exon 1, with the ATG start site indicated).  
        
                              
                                                                    
 











Figure 8. PCR amplification of exons 1-6 of the GAMT Gene. Primer pairs 
expected amplification location shown on right. 
   600- 500- 
300- 
   Size 
     bp 
Markers 
Exon 
    1 
Exons 
   2-3 
Exon 
    4 
Exon 
    5 
Exon 
    6 
Primer Pair   Amplicon  
                       Length                          
                   (base pairs) 
1          554 
2-3          579 
4          211 
5          586 
















  Primers were developed for the GATM Gene (encoding the AGAT 
enzyme) in the same way as described for the GAMT Gene. The AGAT Gene is 
located on chromosome 15 (Edvardson, et al., 2010) and is 16,858 base pairs 
long (Item et al., 2001) (Fig. 10). It is located between base pairs 45,653,324 and 
45,670,980. Exons 4 and 5 along with exons 6 and 7 were close and amplified 
together. Table 4 lists the AGAT primers with the M13 tails. Figure 11 shows 
PCR amplification of all exons of the GATM (AGAT) Gene with Failsafe buffer D 
that proved the most effective. 
 
 
Figure 10. Arginine: glycine amidinotransferase: Schematic of the gene and the 
protein. (Longo et al., 2011) Crystal structure reconstructed with coordinates from 








Table 4. GATM (AGAT) Primers  
 
 








Forward Primer with M13 
Tail (5’-3’) 
Reverse Primer with M13 
Tail (5’-3’) 


























































Primers designed July 22, 2010 using UCSC Genome browser.  M13 tails are in 
black. 










Figure 11. PCR amplification of all exons of the GATM (AGAT) Gene. Primer 
pairs expected amplification location shown on the right. 
Exon 
    3 Exon 
   2 
Exon 






    8 
Exon 
   9 
Markers Size 
bp 
Primer Pair     Amplicon 
           Length (bp) 
 
1             226 
2  394 
3  415 
4-5  682 
6-7  292 
8  336 

















 GAMT and AGAT deficiencies are serious brain creatine deficiency 
disorders that result in mental retardation and seizures. The disorders may be 
under diagnosed due to nonspecific symptoms. These syndromes must be 
diagnosed as early as possible to prevent irreversible brain damage. Here we 
present a new three-tier testing method that is effective for testing dried blood 




Significance of Findings 
 
 The primary screen by tandem mass spectroscopy was able to detect 
guanidinoacetate and creatine in dried blood spots at various concentrations. 
The second tier test confirmed quantitatively the abnormal guanidinoacetate in 
these samples. The third tier test, DNA testing, will further differentiate other 
causes of elevated guanidinoacetate from GAMT deficiency. This system can be 
easily included in the current screen, without the need to collect additional 
samples and with minimal additional cost. Only the cost of the internal standards 





addition to the cost of DNA testing. With this study, we have shown that there is 
no interference in the recovery of guanidinoacetate when extracting amino acids 
and acylcarnitines and, vice versa. The implementation of this screening would 
allow early treatment and improved outcome. The GAMT and GATM Gene 




Limitations and Future Work 
 
 The next step is to optimize DNA extraction from leftover newborn dried 
blood spots. Each punch from a dried blood spot, depending on the size, 
contains 3-8 µL of blood. Methods are available for efficient extraction of DNA 
from these small samples, and only a small amount of DNA is required for the 
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